Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months
01:33pm, Monday, 28'th Mar 2022
Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.
IGA: Deep Discount, 8.25% Distribution Yield
06:58am, Sunday, 27'th Mar 2022
IGA: Deep Discount, 8.25% Distribution Yield
AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study
06:24pm, Friday, 25'th Mar 2022 Zacks Investment Research
AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.
Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?
03:49pm, Friday, 25'th Mar 2022 Zacks Investment Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
Biotech Stock Roundup: BMY's Drug Approval, MRNA's Vaccine Update & More
05:34pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Pipeline and regulatory updates from Bristol Myers (BMY) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
This Beaten-Down Dividend Stock Is Still a Buy
10:50am, Wednesday, 23'rd Mar 2022 The Motley Fool
Alexandria offers a great combination of growth and stability.
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
09:45pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.82, marking a -0.32% move from the previous day.
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
09:50pm, Monday, 21'st Mar 2022 Zacks Investment Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.05, marking a +0.04% move from the previous day.
Bristol Myers' (BMY) Opdualag Wins FDA Nod for Melanoma
03:23pm, Monday, 21'st Mar 2022 Zacks Investment Research
Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.
Amgen (AMGN) Outperforms Industry This Year So Far: What Next?
01:05pm, Monday, 21'st Mar 2022 Zacks Investment Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Bristol Myers' (BMY) Opdualag Wins FDA Nod for Melanoma
12:48pm, Monday, 21'st Mar 2022
Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.
Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?
11:41am, Monday, 21'st Mar 2022 Zacks Investment Research
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Value investing is back: Here’s how to dodge the losers and spot the winners — with five stocks to consider
02:32pm, Saturday, 19'th Mar 2022 MarketWatch
Look for companies with high free cash flow and built-in inflation protection.
Bristol Myers Squibb: Still On Track
08:40am, Saturday, 19'th Mar 2022
Despite facing a steep patent cliff, BMY has one of the largest pipelines of the US pharmaceuticals. Recent and upcoming launches should replace lost revenue to support continued modest growth.
